AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 156 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,796,177 | -23.3% | 274,593 | -12.3% | 0.00% | 0.0% |
| Q2 2023 | $8,864,331 | -20.1% | 313,006 | -35.2% | 0.00% | 0.0% |
| Q1 2023 | $11,090,651 | +49.9% | 482,832 | +83.3% | 0.00% | 0.0% |
| Q4 2022 | $7,398,267 | -7.7% | 263,471 | -7.0% | 0.00% | 0.0% |
| Q3 2022 | $8,015,000 | +123.0% | 283,397 | +74.8% | 0.00% | – |
| Q2 2022 | $3,594,000 | -53.8% | 162,161 | -39.3% | 0.00% | -100.0% |
| Q1 2022 | $7,776,000 | -16.2% | 267,137 | -5.3% | 0.00% | 0.0% |
| Q4 2021 | $9,275,000 | +47.3% | 282,180 | +106.8% | 0.00% | 0.0% |
| Q3 2021 | $6,298,000 | -31.2% | 136,461 | -17.9% | 0.00% | 0.0% |
| Q2 2021 | $9,155,000 | +18.0% | 166,116 | +10.5% | 0.00% | 0.0% |
| Q1 2021 | $7,759,000 | +31.2% | 150,264 | +10.1% | 0.00% | 0.0% |
| Q4 2020 | $5,914,000 | +4.5% | 136,499 | -15.5% | 0.00% | 0.0% |
| Q3 2020 | $5,657,000 | -38.2% | 161,623 | -5.6% | 0.00% | 0.0% |
| Q2 2020 | $9,155,000 | +2.6% | 171,190 | -31.9% | 0.00% | -50.0% |
| Q1 2020 | $8,919,000 | -26.9% | 251,406 | -1.7% | 0.00% | 0.0% |
| Q4 2019 | $12,206,000 | +161.8% | 255,633 | +77.6% | 0.00% | +100.0% |
| Q3 2019 | $4,663,000 | +18.0% | 143,928 | +81.7% | 0.00% | 0.0% |
| Q2 2019 | $3,951,000 | -79.4% | 79,208 | -72.1% | 0.00% | -50.0% |
| Q1 2019 | $19,134,000 | +136.8% | 283,709 | +61.9% | 0.00% | +100.0% |
| Q4 2018 | $8,079,000 | +922.7% | 175,196 | +1611.4% | 0.00% | – |
| Q3 2018 | $790,000 | -70.1% | 10,237 | -67.3% | 0.00% | – |
| Q2 2018 | $2,640,000 | -45.3% | 31,345 | -46.9% | 0.00% | – |
| Q1 2018 | $4,824,000 | +868.7% | 58,994 | +577.1% | 0.00% | – |
| Q4 2017 | $498,000 | -65.8% | 8,713 | -60.0% | 0.00% | – |
| Q3 2017 | $1,456,000 | -1.0% | 21,807 | -23.7% | 0.00% | – |
| Q2 2017 | $1,471,000 | -41.6% | 28,575 | -33.8% | 0.00% | -100.0% |
| Q1 2017 | $2,520,000 | +35.8% | 43,143 | -3.0% | 0.00% | – |
| Q4 2016 | $1,856,000 | +10.5% | 44,477 | +39.9% | 0.00% | – |
| Q3 2016 | $1,679,000 | -37.8% | 31,793 | -50.7% | 0.00% | -100.0% |
| Q2 2016 | $2,700,000 | +6.3% | 64,452 | +3.0% | 0.00% | 0.0% |
| Q1 2016 | $2,541,000 | -36.3% | 62,593 | +2.0% | 0.00% | 0.0% |
| Q4 2015 | $3,986,000 | +3.4% | 61,395 | +12.4% | 0.00% | 0.0% |
| Q3 2015 | $3,854,000 | +105.7% | 54,601 | +223.8% | 0.00% | 0.0% |
| Q2 2015 | $1,874,000 | +452.8% | 16,861 | +368.8% | 0.00% | – |
| Q1 2015 | $339,000 | +26.5% | 3,597 | +50.5% | 0.00% | – |
| Q4 2014 | $268,000 | +104.6% | 2,390 | +11.7% | 0.00% | – |
| Q3 2014 | $131,000 | -57.3% | 2,139 | -68.1% | 0.00% | – |
| Q2 2014 | $307,000 | +30600.0% | 6,710 | +51515.4% | 0.00% | – |
| Q1 2014 | $1,000 | -98.6% | 13 | -99.6% | 0.00% | – |
| Q4 2013 | $72,000 | – | 3,005 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |